Clinical Trial Update: Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Doxil and vintafolide for platinum-resistant ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Vintafolide (EC145) (vintafolide)

Snippet

Sponsor: Endocyte | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED